Stockreport

Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects [Yahoo! Finance]

Taysha Gene Therapies, Inc.  (TSHA) 
PDF The trial is evaluating TSHA-102, a gene therapy for Rett syndrome. The trial is poised to evaluate 15 females between the ages of 6 and 22 years with Rett syndrome. T [Read more]